Navigation Links
URL Pharma Launches Co-Pay Assistance Program for Colcrys(R)
Date:12/23/2009

PHILADELPHIA, Dec. 23 /PRNewswire/ -- URL Pharma today announced the launch of the Colcrys® (colchicine, USP) Co-Pay Assistance Program, an initiative designed to save patients money on their health insurance co-payment for Colcrys. The co-pay assistance program allows many patients to pay no more than $25 for a Colcrys prescription, which equates to savings of up to $65 per prescription. Colcrys is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever (FMF).

The Colcrys Co-Pay Assistance Program is accessible via two simple options:

  • Patients can receive co-pay assistance by having their Colcrys prescriptions filled at any of more than 32,000 pharmacies nationwide that participate in the evoucherRx(TM) program from Relay Health. For a listing of pharmacies participating in the evoucherRx program, please visit http://evoucherrx.relayhealth.com/storelookup.
  • Patients may obtain a co-pay assistance coupon directly from their doctor's office and present it to their pharmacist when filling a Colcrys prescription. The coupon can be used up to eight times with a valid Colcrys prescription. URL Pharma is working to provide a downloadable co-pay assistance coupon on the Colcrys web site (www.colcrys.com) in the near future.

"URL Pharma recognizes that given the current economic climate, out-of-pocket costs for medications may be increasingly challenging for patients," said Richard H. Roberts, MD, PhD, President, CEO and Chairman of URL Pharma. "The Colcrys Co-Pay Assistance Program is designed to be easily accessible and widely available so patients with gout or FMF can continue to receive the medications they need and experience significant cost savings."

Patients with questions about the Colcrys Co-Pay Assistance program may call 1-800-657-7613 from 8:00 AM - 8:00 PM EST from Monday through Friday.

For patients who are uninsured or underinsured, URL Pharma offers its medications at a reduced cost to those who qualify through the company's Patient Assistance Program. For more information on the patient assistance program, please visit www.rxoutreach.com or call 1-800-769-3880.

The Colcrys Co-Pay Assistance Program will be in effect until August 11, 2010. The program is valid only for patients with primary coverage and with a Colcrys prescription written for 30 tablets or more. The coupon is not valid in Massachusetts, or for prescriptions paid for in part or in full by any state or federally funded program including, but not limited to, Medicare, Medicaid, Medigap, VA, DOD, or TriCare and where prohibited by law. The coupon is also not valid for cash-paying patients or rejected claims.

Important Safety Information

Colcrys (colchicine, USP) tablets are indicated for the prophylaxis and treatment of gout flares in adults and for the treatment of Familial Mediterranean Fever.

Colcrys is contraindicated in patients with renal or hepatic impairment who are concurrently prescribed P-gp inhibitors or strong inhibitors of CYP3A4 as life-threatening or fatal toxicity has been reported. The most common adverse events in clinical trials for the prophylaxis and treatment of gout were diarrhea and pharyngolaryngeal pain. Rarely, myelosuppression, thrombocytopenia, and leukopenia have been reported in patients taking colchicine. Rhabdomyolysis has been occasionally observed, especially when colchicine is prescribed in combination with other drugs known to cause this effect. Monitoring is recommended for patients with a history of blood dyscrasias or rhabdomyolysis.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You may also report negative side effects to the manufacturer of Colcrys by calling 1-888-351-3786. Please see www.colcrys.com for full prescribing information.

About URL Pharma

URL Pharma, Inc., headquartered in Philadelphia, PA, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a technology-driven, specialty pharmaceutical business. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medical needs for improvements in safety and efficacy. For additional information about the company, please visit www.urlpharma.com.

For further information, please call 215-697-1900 or e-mail us at media@urlpharma.com.

SOURCE URL Pharma, Inc.


'/>"/>
SOURCE URL Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PDI Announces New Pharmaceutical Services Business Win With a Top 5 Pharmaceutical Company
2. National Pharmaceutical Council Welcomes New Member, Otsuka America Pharmaceutical, Inc.
3. CVS/pharmacy to Provide H1N1 Vaccinations in Rhode Island by End of Week
4. Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp.
5. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
6. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
7. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
8. PDL BioPharma Announces New Licensing Agreement With Eli Lilly
9. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
10. Raptor Pharmaceutical Corp. Announces $7.5 Million Securities Offering
11. ISTA Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Once-Daily XiDay(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... LONDON , Dec. 6, 2016 ... report provides in-depth region wise and country wise ... this report include manufacturers of human vaccines products, ... players planning to enter the market. The ... global human vaccines market. Qualitative analysis comprises market ...
(Date:12/6/2016)... Dec. 6, 2016 Eurofins Genomics today ... the College of American Pathologists (CAP) and certification ... its new laboratory in Louisville, KY ... North American headquarters. "Our new CLIA-licensed ... which is still considered the ,Gold Standard, method ...
(Date:12/6/2016)... , Dec. 6, 2016  BTL Aesthetics today ... that its BTL Vanquish ME device was effectively ... delivery to the targeted tissue. The result: Significantly ... higher, with BTL Vanquish ME versus BTL Vanquish. ... physician network and their patients with the most ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back ... not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... the children of the world. , In exchange for generous donations, customers will receive ...
(Date:12/7/2016)... ... 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... of America, declared on her radio program in November 2016 the need to educate ... bullies attack leaders in corporate America, they are trying to take advantage of successful ...
(Date:12/7/2016)... Phoenix, Arizona (PRWEB) , ... December 07, 2016 , ... ... Juvederm®, Just in Time For The Holiday Party Season. Save Up To 33% Off ... and Laser Salon is providing the Phoenix Valley with Delightful Deals on ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that ... One major study analyzing heart attacks among 138,602 people recorded a 35% higher number ... We would all agree of course–no time of year is a good time for ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):